Company Interview / The small cap diagnosing autism with a smartphone

Key points:

AI-powered technology provides early detection of autism and ADHD via smartphonesPivotal US trial underway, with data to support FDA approval objectivesPeer-reviewed publication in Autism Research journal boosts clinical credibilityShare price saw significant growth as investors acknowledge progress

BlinkLab (ASX:BB1) is at the forefront of digital health innovation, aiming to transform the early diagnosis of autism and ADHD in children through its AI-powered, smartphone-based tool. Brian Leedman outlines how the technology uses a forward-facing camera to deliver visual and audio stimuli to a child, with AI analysing the response. The goal is to enable quick, accessible testing at home, while ensuring diagnoses are reviewed by a medical professional, in line with regulatory requirements. Leedman highlights BlinkLab's recent $800,000 tax incentive refund under Australia's Research and Development Tax Incentive program and a strong cash position of over $7 million as of September.

The current focus is on a pivotal US trial, comprising more than 500 participants across up to 11 sites. According to Leedman, the FDA requires at least 65% sensitivity and specificity for approval, positioning BlinkLab to potentially disrupt the healthcare sector. The technology's competitive edge is underscored by its exclusive licensing from Princeton University and peer-reviewed validation in the prestigious journal Autism Research.

Leedman sees the ASX as the ideal platform for BlinkLab's growth, citing a share price increase of up to 500% in a year as evidence investors recognise the company's progress. He notes future potential for acquisition by a major player if clinical and regulatory milestones are met.